Moderna (MRNA) Stock Explodes 177% on Cancer Vaccine News. Is the Hype Justified?
TLDR
- Moderna stock jumped 177% in a single session after late-stage trial results showed its personalized mRNA melanoma vaccine reduced cancer recurrence.
- The one-day surge was the largest for an S&P 500 company in over two decades.
- Moderna’s market cap rose from around $25 billion to near $60 billion after the announcement.
- Analysts warn the hype may be running ahead of reality, with one model projecting low-single-digit billions in annual sales by 2032.
- Key concerns include high manufacturing costs, European pricing pressure, and questions about whether the vaccine will work beyond melanoma.
Moderna stock surged 177% on Wednesday after the company and partner Merck reported positive late-stage trial results for their personalized mRNA melanoma vaccine. The move was the largest single-day gain for an S&P 500 company in more than 20 years.
The stock’s market cap jumped from roughly $25 billion to near $60 billion in a single session. Combined with gains at Merck and BioNTech, which is developing its own personalized mRNA cancer vaccine, the three companies added around $80 billion in market value within days.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
